EUVIMEDEUVIMED entdecken
Klinische Studie (Phase IV)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access

Biannual Mass Azithromycin Distributions for Preschool Children and Malaria Parasitemia

Ahmed M Arzika, Amza Abdou, Ramatou Maliki, Elodie Lebas, Catherine Cook, Benjamin Vanderschelden, Kieran S O'Brien, Sun Y Cotter, Nicole E Varnado, E Kelly Callahan, Robin L Bailey, Sheila K West und 5 weitere

JAMA Network Open · 2025

DOI: 10.1001/jamanetworkopen.2025.27148 ↗

Kurz gefasst

Klinische Studie (Phase IV) in der Zeitschrift JAMA Network Open, 2025. Verfasst von Ahmed M Arzika und 16 weiteren Autor:innen. Beteiligte Einrichtung: The Carter Center, Niamey, Niger. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Antimalarials, Azithromycin, Malaria. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Mass azithromycin distributions may reduce malaria parasitemia in the short term, but longer-term effectiveness is unclear.

Objective

To examine whether biannual mass azithromycin distributions are associated with lower rates of malaria parasitemia in preschool children living in Niger. Design, Setting, and Participants A cluster randomized trial was performed from November 23, 2014, until June 9, 2020, as an ancillary trial to a larger trial studying the effect of mass azithromycin on child mortality. Study communities (ie, government-defined health catchment areas) in Niger were randomized in a 1:1 ratio to biannual (ie, twice-yearly) mass administration of azithromycin or placebo to all children aged 1 to 59 months and followed up for 5 years. Data analyses were performed from June 25, 2023, to April 27, 2025.

Intervention

Twice-yearly administration of a single dose of oral azithromycin, 20 mg/kg, or placebo. Main Outcomes and Measures The prevalence of parasitemia 4 years after the community started treatment, assessed in a random sample of 40 children per community.

Results

Among the 30 communities in Niger included in the study at baseline, the 15 communities randomized to azithromycin consisted of 1695 children (mean [SD] age, 30.8 [2.8] months; 858 [51.8%] male) and the 15 communities randomized to placebo consisted of 3031 children (mean [SD] age, 30.6 [2.6] months; 157 [52.0%] male). The mean prevalence of malaria parasitemia at baseline was 8.9% (95% CI, 5.1%-15.7%) in the azithromycin arm and 6.7% (95% CI, 4.0%-12.6%) in the placebo arm. At annual follow-up visits up until month 48, parasitemia was not statistically significantly lower in the azithromycin arm compared with the placebo arm, assuming a 10% prevalence in the placebo arm (−3.3 percentage points [PP]; 95% CI, −5.8 to −0.2 PP; permutation P = .05). The Niger Ministry of Health instituted seasonal malaria chemoprevention (SMC) after the month 36 study visit. Analysis restricted to the period before SMC found significantly less parasitemia in the azithromycin arm compared with the placebo arm (4.8 PP lower; 95% CI, −7.4 to −1.3 PP; permutation P = .02). Conclusions and Relevance In this placebo-controlled cluster randomized trial, malaria among children aged 1 to 59 months was lower in communities treated with biannual mass azithromycin, but the effect was significant only for the first 3 years of the trial, before SMC. Trial Registration ClinicalTrials.gov Identifier: NCT02048007

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsAntimalarialsAzithromycinMalariaMass Drug AdministrationParasitemiaChild, PreschoolFemaleHumansInfantMaleNiger

Substanzen

Anti-Bacterial AgentsAntimalarialsAzithromycin

Autor:innen und Institutionen

  • The Carter Center, Niamey, Niger.
  • Centre de Recherche et Interventions en Santé Publique, Birni N'Gaoure, Niger.
  • Programme Nationale de Santé Oculaire, Niamey, Niger.
  • Francis I. Proctor Foundation, University of California, San Francisco.
  • Department of Ophthalmology, University of California, San Francisco.
  • Department of Epidemiology & Biostatistics, University of California, San Francisco.

Zitieren

APA

Arzika, A. M., Abdou, A., Maliki, R., Lebas, E., Cook, C., Vanderschelden, B., O'Brien, K. S., Cotter, S. Y., Varnado, N. E., Callahan, E. K., Bailey, R. L., West, S. K., Rosenthal, P. J., Porco, T. C., Lietman, T. M., Keenan, J. D., & MORDOR-Niger Study Group (2025). Biannual Mass Azithromycin Distributions for Preschool Children and Malaria Parasitemia. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2025.27148

Vancouver

Arzika AM, Abdou A, Maliki R, Lebas E, Cook C, Vanderschelden B, et al. Biannual Mass Azithromycin Distributions for Preschool Children and Malaria Parasitemia. JAMA Network Open. 2025. doi:10.1001/jamanetworkopen.2025.27148

BibTeX
@article{Arzika2025,
  author = {Arzika, Ahmed M and Abdou, Amza and Maliki, Ramatou and Lebas, Elodie and Cook, Catherine and Vanderschelden, Benjamin and O'Brien, Kieran S and Cotter, Sun Y and Varnado, Nicole E and Callahan, E Kelly and Bailey, Robin L and West, Sheila K and Rosenthal, Philip J and Porco, Travis C and Lietman, Thomas M and Keenan, Jeremy D and MORDOR-Niger Study Group, MORDOR-Niger Study Group},
  title = {Biannual Mass Azithromycin Distributions for Preschool Children and Malaria Parasitemia},
  journal = {JAMA Network Open},
  year = {2025},
  doi = {10.1001/jamanetworkopen.2025.27148}
}
Kostenlos starten →